Skip to Content
Merck
All Photos(1)

Documents

I2411

Sigma-Aldrich

Isocitrate Dehydrogenase 1 (NADP+) human

recombinant, expressed in Sf9 cells, ≥90% (SDS-PAGE)

Synonym(s):

IDH1, Isocitrate Dehydrogenase Cytoplasmic

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
9028-48-2
Enzyme Commission number:
1.1.1.42 (BRENDA, IUBMB)
UNSPSC Code:
12352204
NACRES:
NA.54

recombinant

expressed in Sf9 cells

Assay

≥90% (SDS-PAGE)

form

buffered aqueous glycerol solution

mol wt

47.6 kDa

concentration

≥0.30 mg/mL protein (Bradford)

NCBI accession no.

NM_005896

relevant disease(s)

cancer (lung)

shipped in

dry ice

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

General description

Human Isocitrate Dehydrogenase (IDH1), also known as oxalosuccinate decarboxylase, full length [amino acids 1-414 (end)] with C-terminal FLAG-tag, expressed in Sf9 cells via a baculovirus expression system.

Application

Human Isocitrate Dehydrogenase (IDH1) is useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling. It may be useful as a biomarker for diagnosis and prognosis prediction of non-small cell lung cancer .

Biochem/physiol Actions

Human Isocitrate Dehydrogenase (IDH1), also known as oxalosuccinate decarboxylase, is a full length amino acid with a C-terminal FLAG-tag and is expressed in Sf9 cells via a baculovirus expression system. IDH1 expression has been correlated with poor survival of non-small cell lung cancer. IDH1 promotes tumor growth .

Physical form

Solution in 45 mM Tris-HCl, 124 mM NaCl, 2.4 mM KCl, 90 μg/ml FLAG peptide, 3 mM DTT, and 10% glycerol at pH 8.0.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

NADP Disodium salt

Roche

NADP-RO

NADP

β-Nicotinamide adenine dinucleotide phosphate hydrate

Sigma-Aldrich

N5755

β-Nicotinamide adenine dinucleotide phosphate hydrate

Peter Paschka et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(22), 3636-3643 (2010-06-23)
To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML). We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study
Fengwei Tan et al.
Molecular & cellular proteomics : MCP, 11(2), M111-M111 (2011-11-09)
Lung cancer is the leading cause of cancer-related death in the world. To explore tumor biomarkers for clinical application, two-dimensional fluorescence difference gel electrophoresis and subsequent MALDI-TOF/TOF mass spectrometry were performed to identify proteins differentially expressed in 12 pairs of
Lenny Dang et al.
Trends in molecular medicine, 16(9), 387-397 (2010-08-10)
The systematic sequencing of glioblastoma multiforme (GBM) genomes has identified the recurrent mutation of IDH1, a gene encoding NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) that catalyzes the oxidative decarboxylation of isocitrate yielding alpha-ketoglutarate (alpha-KG). Subsequent studies have confirmed recurrent IDH1 and
Yuejun Fu et al.
Biochemical and biophysical research communications, 397(2), 127-130 (2010-06-01)
Heterozygous mutations in either the R132 residue of isocitrate dehydrogenase I (IDH1) or the R172 residue of IDH2 in human gliomas were recently highlighted. Heterozygous mutations in the IDH1 occur in the majority of grade II and grade III gliomas
Yui Mano et al.
Journal of neurosurgery. Pediatrics, 11(5), 518-525 (2013-02-26)
Dysembryoplastic neuroepithelial tumors (DNETs) have conventionally been regarded as benign and stable tumors and considered curable with surgery without adjunctive therapy. Recently, recurrent DNETs with or without malignant transformation have been described. The authors report 2 unusual cases of DNET:
View All Related Papers

Protocols

Chiral LC-MS/MS of D- and L-2-Hydroxyglutaric Acid Biomarkers

We describe here a rapid and sensitive method to separate and measure D-2-OHG and L-2-OHG enantiomers using high-resolution mass spectrometry (HRMS) detection.

Chromatograms

application for HPLC

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service